Clinical trialNCT06011798CompletedPhase 2Interventional

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

SponsorUnity Biotechnology, Inc.Enrollment52Diabetes MellitusDiabetic Macular EdemaDiabetic RetinopathyEdemaEye DiseasesMacular Edema+3 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are: * Assess the efficacy of foselutoclax compared to aflibercept * Assess the safety and tolerability of foselutoclax

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert Bhisitkul, MD, Ph.D.
Unity Biotechnology, Inc.
Study DirectorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

California Retina Consultants
Bakersfield, California, United States
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
Salehi Retina Institute Inc.
Huntington Beach, California, United States
Bay Area Retina Associates
Walnut Creek, California, United States
Advanced Vision Research Institute
Longmont, Colorado, United States
Rand Eye Institute
Deerfield Beach, Florida, United States
Florida Eye Associates
Melbourne, Florida, United States
Retina Vitreous Associates of Florida
St. Petersburg, Florida, United States
University Retina and Macula Associates
Lemont, Illinois, United States
Midwest Eye
Carmel, Indiana, United States
Cumberland Valley Retina Consultants
Hagerstown, Maryland, United States
Sierra Eye Associates
Reno, Nevada, United States
Eyehealth Northwest
Portland, Oregon, United States
Erie Retina Research, Llc
Erie, Pennsylvania, United States
Vision Research Solutions, Pllc
Philadelphia, Pennsylvania, United States
Retina Consultants of Carolina
Greenville, South Carolina, United States
Retina Research Institution of Texas
Abilene, Texas, United States
Austin Retina Associates
Round Rock, Texas, United States
Retina Center of Texas
Southlake, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Aflibercept →Foselutoclax

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 23 Aug 2023
Primary completion: 21 Jan 2025
Completion: 8 Apr 2025
Last update posted: 5 Aug 2025
Registered enrollment: 52
Registry id: NCT06011798

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.